Key Details
Price
$0.45Annual ROE
-155.00%Beta
0.15Events Calendar
Next earnings date:
Feb 07, 2025Recent quarterly earnings:
Nov 08, 2024Recent annual earnings:
May 28, 2020Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Aug 19, 2020Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its oral presentation of its lead clinical stage drug FXR314 by Dr. Eric Lawitz of the Texas Liver Institute and the University of Texas Health San Antonio was featured at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The meeting was held November 15-19, 2024 in San Diego, California.
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its lead clinical stage drug, FXR314 will be featured in an oral presentation at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The presentation, by Dr. Eric Lawitz of the Texas Liver Institute, will describe the findings from the FXR314 Phase 2 MASH study. The meeting will be held November 15-19, 2024 in San Diego, California.
Nio Inc (NYSE: NIO) opened more than 10% up on Thursday after a JPMorgan analyst issued a super bullish note in its favour. Nick Lai now sees upside in the EV stock to $8.0.
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that Executive Chairman Keith Murphy presented on the company's near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA. The webcast was recorded and can be viewed at https://wsw.com/webcast/jones/onvo/1848798.
Organovo is scheduled to share information about its primary clinical-stage medication, FXR314, at DDW2024, taking place in Washington, D.C. from May 18-21, 2024.
Organovo Holdings announced on Monday that its experimental drug for a certain type of fatty liver disease achieved the primary objective in a mid-stage trial, causing its stock to rise by almost 27% in premarket trading.
SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fidelity in three-dimensional (3D) human tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Founder and Executive Chairman, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.
FAQ
- What is the primary business of Organovo Holdings?
- What is the ticker symbol for Organovo Holdings?
- Does Organovo Holdings pay dividends?
- What sector is Organovo Holdings in?
- What industry is Organovo Holdings in?
- What country is Organovo Holdings based in?
- When did Organovo Holdings go public?
- Is Organovo Holdings in the S&P 500?
- Is Organovo Holdings in the NASDAQ 100?
- Is Organovo Holdings in the Dow Jones?
- When was Organovo Holdings's last earnings report?
- When does Organovo Holdings report earnings?
- Should I buy Organovo Holdings stock now?